Skip to Content

Virtus LifeSci Biotech Products ETF BBP

Medalist Rating as of | See Virtus Investment Hub

Morningstar’s Analysis BBP

Will BBP outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Virtus LifeSci Biotech Products ETF's Average Process Pillar and People Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the second-cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings BBP

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 27.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Tarsus Pharmaceuticals Inc Ordinary Shares

3.66 671,773
Healthcare

ADMA Biologics Inc

3.36 616,800
Healthcare

Agios Pharmaceuticals Inc

2.84 521,525
Healthcare

SpringWorks Therapeutics Inc Ordinary Shares

2.63 483,428
Healthcare

Moderna Inc

2.61 478,708
Healthcare

Sarepta Therapeutics Inc

2.57 472,111
Healthcare

Lexicon Pharmaceuticals Inc

2.57 471,878
Healthcare

Ascendis Pharma A/S ADR

2.50 459,401
Healthcare

Neurocrine Biosciences Inc

2.40 439,883
Healthcare

Intra-Cellular Therapies Inc

2.35 431,700
Healthcare